Patents by Inventor Stefan Dengl

Stefan Dengl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-HLA-G ANTIBODIES AND USE THEREOF
    Publication number: 20210147553
    Abstract: The present invention relates to anti-HLA-G antibodies and methods of using the same.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 20, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Sebastian FENN, Jens FISCHER, Andreas HINZ, Claudia KIRSTENPFAD, Stefan KLOSTERMANN, Joerg MOELLEKEN, Georg TIEFENTHALER, Sabine HOVES, Alexander BUJOTZEK, Meher MAJETY
  • MULTISPECIFIC ANTIBODIES AND USE THEREOF
    Publication number: 20210147554
    Abstract: The present invention relates to multispecific antibodies that bind to HLA-G ant to a T cell activating antigen, their preparation, formulations and methods of using the same.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 20, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Sebastian FENN, Jens FISCHER, Claudia KIRSTENPFAD, Stefan KLOSTERMANN, Joerg MOELLEKEN, Georg TIEFENTHALER, Alexander BUJOTZEK, Meher MAJETY, Silke KIRCHNER
  • HUMANIZED ANTI-TAU(PS422) ANTIBODIES AND METHODS OF USE
    Publication number: 20210139571
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: September 17, 2020
    Publication date: May 13, 2021
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • ANTI-VEGF ANITBODIES AND METHODS OF USE
    Publication number: 20210079080
    Abstract: The present invention relates to anti-VEGF antibodies and methods of their production and their use.
    Type: Application
    Filed: June 26, 2020
    Publication date: March 18, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Sebastian Fenn, Guy Georges, Joerg Moelleken, Francesca Ros, Esther Koenigsberger
  • STABILIZED IMMUNOGLOBULIN DOMAINS
    Publication number: 20210054021
    Abstract: The invention relates autonomous VH domains (aVH) with cysteines in positions 52a and 71 or in positions 33 and 52 in order to stabilize the autonomous VH domains. Said cysteines are capable of forming a disulfide bond and/or form a disulfide bond under suitable conditions. The invention further relates to aVH libraries.
    Type: Application
    Filed: July 30, 2020
    Publication date: February 25, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Deak Codarri, Stefan Dengl, Jens Fischer, Thomas Hofer, Laurent Lariviere, Ekkehard Moessner, Stefan Seeber, Pablo Umana, Anne-Claire Zagdoun
  • METHOD FOR IMPROVING VEGF-RECEPTOR BLOCKING SELECTIVITY OF AN ANTI-VEGF ANTIBODY
    Publication number: 20210047395
    Abstract: The present invention relates to methods for improving anti-VEGF antibodies in order to provide or improve antibodies that preferentially inhibit binding to VEGF to VEGF-R2 rather than VEGF binding to VEGF-R1; and antibodies provided by said methods.
    Type: Application
    Filed: June 26, 2020
    Publication date: February 18, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg Benz, Stefan Dengl, Sebastian Fenn, Joerg Moelleken, Andreas Ehler
  • Antibodies binding to NKG2D
    Publication number: 20210032349
    Abstract: The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: July 14, 2020
    Publication date: February 4, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Guy GEORGES, Ralf HOSSE, Inja WALDHAUER, Christian KLEIN, Pablo UMANA
  • METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
    Publication number: 20200392253
    Abstract: Herein is reported a method for the generation of multispecific antibodies by a half-antibody exchange reaction between two 2/3-IgGs destabilized in one half by asymmetric perturbing mutations fostering the generation of correctly assemble full length bispecific antibodies. The method can be performed in the absence of reducing agents and does not require hinge region disulfide bonds in the starting 2/3-IgGs.
    Type: Application
    Filed: April 15, 2020
    Publication date: December 17, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Stefan Dengl, Guy Georges, Eike Hoffmann, Klaus Mayer, Felix Bormann
  • BISPECIFIC ANTIBODIES COMPRISING AN ANTIGEN-BINDING SITE BINDING TO LAG3
    Publication number: 20200354457
    Abstract: The invention relates to novel antibodies particularly suitable for cancer therapies. The antibodies according to the invention are bispecific or multispecific antibodies and comprise a first antigen binding site that binds to LAG3. The first antigen binding site is an autonomous VH domain.
    Type: Application
    Filed: January 30, 2019
    Publication date: November 12, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Stefan Dengl, Jens Fischer, Thomas Hofer, Laurent Lariviere, Ekkehard Moessner, Stefan Seeber, Pablo Umaña
  • Humanized anti-tau(pS422) antibodies and methods of use
    Patent number: 10822402
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: November 3, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2
    Patent number: 10808038
    Abstract: The invention relates to HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2, their preparation and use as medicament.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: October 20, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Birgit Bossenmaier, Richard Buick, Stefan Dengl, Michael Gerg, Carmen Peess, Wolfgang Schaefer, Michael Schraeml, Claudio Sustmann
  • Bispecific antibodies and methods of use in ophthalmology
    Patent number: 10730938
    Abstract: Herein are reported novel bispecific antibodies that specifically bind to two different antigens selected from the group consisting of human ANG2, human VEGF, human IL-1beta and human PDGF-B.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: August 4, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marc Bedoucha, Sebastian Breuer, Stefan Dengl, Christian Gassner, Guy Georges, Sabine Gruener, Guido Hartmann, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Olaf Mundigl, Joerg Thomas Regula, Ralf Schumacher, Barbara Weiser
  • ANTIBODY THAT BINDS TO VEGF AND IL-1BETA AND METHODS OF USE
    Publication number: 20200199214
    Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
    Type: Application
    Filed: December 20, 2019
    Publication date: June 25, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ROLAND BECKMANN, JOERG BENZ, STEFAN DENGL, CHRISTIAN GASSNER, GUIDO HARTMANN, PETER MICHAEL HUELSMANN, SABINE IMHOF-JUNG, KRISTIAN HOBOLT JENSEN, HUBERT KETTENBERGER, STEFAN LORENZ, JOERG MOELLEKEN, OLAF MUNDIGL
  • COVALENTLY LINKED ANTIGEN-ANTIBODY CONJUGATES
    Publication number: 20200164064
    Abstract: Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.
    Type: Application
    Filed: October 29, 2019
    Publication date: May 28, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Ulrich BRINKMANN, Stefan DENGL, Sebastian DZIADEK, Guy GEORGES, Michael GROTE, Alexander HAAS, Eike HOFFMANN
  • METHOD FOR PRODUCING MONOMERIC AND MULTIMERIC MOLECULES AND USES THEREOF
    Publication number: 20200157183
    Abstract: Herein is reported a method for the production of a polypeptide that is biologically active as n-mer comprising a nucleic acid encoding a fusion polypeptide according to the following formula (Bn-CSo-Is-CSp-FC-CSq-It-CSr-Bm)u, wherein B denotes a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region, FC denotes a heavy chain Fc-region polypeptide, CS denotes a cleavage site, and I denotes an intervening amino acid sequence, wherein FC does not substantially bind to an Fc-receptor, recovering the fusion polypeptide from the cell or the cultivation medium, optionally cleaving the fusion polypeptide with a protease, and thereby producing a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 21, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Johannes Auer, Martin Bader, Stefan Dengl, Stefan Lorenz, Stefan Seeber
  • ANTI-TPBG ANTIBODIES AND METHODS OF USE
    Publication number: 20200108154
    Abstract: The invention provides anti-TPBG antibodies and methods of using the same.
    Type: Application
    Filed: August 28, 2019
    Publication date: April 9, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Sebastian FENN, Jen FISCHER, Thomas FRIESS, Sabine IMHOF-JUNG, Ben-Fillippo KRIPPENDORFF, Christian SCHANTZ, Tilman SCHLOTHAUER, Claudio SUSTMANN, Barbara WEISER, Adrian ZWICK
  • ANTI-HLA-G ANTIBODIES AND USE THEREOF
    Publication number: 20200102389
    Abstract: The present invention relates to anti-HLA-G antibodies and methods of using the same.
    Type: Application
    Filed: May 17, 2019
    Publication date: April 2, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jens FISCHER, Meher MAJETY, Stefan DENGL, Georg TIEFENTHALER, Stefan KLOSTERMANN, Claudia KIRSTENPFAD, Esther KOENIGSBERGER, Francesca ROS
  • Method for producing monomeric and multimeric molecules and uses thereof
    Patent number: 10570188
    Abstract: Herein is reported a method for the production of a polypeptide that is biologically active as n-mer comprising a nucleic acid encoding a fusion polypeptide according to the following formula (Bn-CSo-Is-CSp-FC-CSq-ItCSr-Bm)u, wherein B denotes a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region, FC denotes a heavy chain Fc-region polypeptide, CS denotes a cleavage site, and I denotes an intervening amino acid sequence, wherein FC does not substantially bind to an Fc-receptor, recovering the fusion polypeptide from the cell or the cultivation medium, optionally cleaving the fusion polypeptide with a protease, and thereby producing a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: February 25, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Auer, Martin Bader, Stefan Dengl, Stefan Lorenz, Stefan Seeber
  • ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH TAILORED AFFINITY
    Publication number: 20200055931
    Abstract: Herein is reported an anti-transferrin receptor antibody that specifically binds to human transferrin receptor and cynomolgus transferrin receptor, which comprises i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO: 01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO: 26, wherein the antibody has an off-rate for the human transferrin receptor that is equal to or less than (i.e. at most) the off-rate of the anti-transferrin receptor antibody 128.1 for the cynomolgus transferrin receptor, whereby the off-rates are determined by surface plasmon resonance, and whereby the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO: 64 and a light chain variable domain of SEQ ID NO: 65.
    Type: Application
    Filed: April 29, 2019
    Publication date: February 20, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Ulrich Goepfert, Jens Niewoehner, Tilman Schlothauer
  • Anti-ANG2 antibodies and methods of use
    Patent number: 10538585
    Abstract: Herein are reported anti-ANG2 antibodies. A specific anti-ANG2 antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: January 21, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Joerg Thomas Regula